CorePath Laboratories is partnering with Genomic Testing Cooperative (GTC) to enhance its next-generation sequencing (NGS) capabilities for cancer diagnostics. This collaboration combines targeted DNA and RNA profiling with other pathology testing methods, providing comprehensive evaluations of patient samples. Additionally, liquid biopsy capabilities offer a non-invasive way to monitor therapy and detect relapse.